Status:

COMPLETED

Safety, Tolerability, and Pharmacokinetic Study of EVP-6124 in Patients With Alzheimer's Disease

Lead Sponsor:

FORUM Pharmaceuticals Inc

Collaborating Sponsors:

Syneos Health

Conditions:

Alzheimer's Disease

Central Nervous System Diseases

Eligibility:

All Genders

50-90 years

Phase:

PHASE1

Brief Summary

This study is being conducted to determine the safety, tolerability, and pharmacokinetics (PK) of three different doses of an investigational medication, EVP-6124, in individuals with mild to moderate...

Detailed Description

This is a randomized, double-blind, placebo-controlled, Phase 1b safety study of three dose levels of EVP-6124 in subjects with mild or moderate Alzheimer's disease and who are taking an AChEI medicat...

Eligibility Criteria

Inclusion

  • male and post-menopausal or surgically sterile female pts
  • 50-90 yrs old, who meet clinical criteria for probable Alzheimer's disease (Mini-Mental State Examination of 18-26; Hachinski Ischemic Score ≤4)
  • must be taking donepezil or rivastigmine for at least 3 mos.

Exclusion

  • Unstable medical condition that is clinically significant in the judgment of the investigator; major organ system dysfunction
  • Untreated hypothyroidism
  • Insufficiently controlled diabetes mellitus
  • Diagnosis of major depression requiring antidepressant medications within the last 5 years
  • Stroke within 6 months before screening, or concomitant with onset of dementia
  • Certain concomitant medications

Key Trial Info

Start Date :

October 1 2008

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

March 1 2009

Estimated Enrollment :

49 Patients enrolled

Trial Details

Trial ID

NCT00766363

Start Date

October 1 2008

End Date

March 1 2009

Last Update

April 20 2012

Active Locations (4)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (4 locations)

1

Pacific Research Network, Inc.

San Diego, California, United States, 92103

2

MD Clinical

Hallandale, Florida, United States, 33009

3

Comprehensive Clinical Research

Berlin, New Jersey, United States, 08009

4

Global Medical Institutes, LLC

Princeton, New Jersey, United States, 08540

Safety, Tolerability, and Pharmacokinetic Study of EVP-6124 in Patients With Alzheimer's Disease | DecenTrialz